Summit Therapeutics Inc
2 ballot items.
Stockholders will vote on increasing the authorized common stock by 1,000,000,000 shares and on any other business properly brought before the Special Meeting.
On the ballot2
- 1
Amendment to the Charter to Increase the Authorized Number of Shares of Common Stock
ManagementBoard: FORApprove an amendment to the Restated Certificate of Incorporation increasing authorized common stock from 1,000,000,000 shares to 2,000,000,000 shares, primarily to support conversion of preferred stock issued in a $2.0 billion private placement and provide flexibility for capital raising, strategic transactions, equity compensation, and other corporate purposes.
More detail
Proposal 1 asks stockholders to approve an amendment to Summit’s Restated Certificate of Incorporation that would double authorized common stock from 1.0 billion to 2.0 billion shares. The additional shares would remain part of the existing common-stock class and would carry the same rights and privileges as currently outstanding common stock. A central reason for the request is the Company’s obligation under a securities purchase agreement to make enough shares available for conversion of Class A Convertible Preferred Stock issued to AstraZeneca Holdings B.V. in a $2.0 billion private placement. The preferred shares are convertible into approximately 108.96 million common shares, but Summit states that its current authorized and unreserved shares are insufficient for that conversion. The additional authorization would also support potential ATM-program sales, other equity or convertible financings, strategic transactions, equity compensation, and general corporate purposes without another stockholder vote. Approval would not itself immediately dilute existing holders, although subsequent issuances could dilute earnings per share, book value, voting power, and percentage ownership and could depress the stock price. If the amendment is not approved and the required increase is not timely filed, the preferred shares may become redeemable, potentially creating a significant expense, while the Company could lose financing flexibility and face risks to its ability to continue as a going concern. The proposal also acknowledges a possible anti-takeover effect because newly authorized shares could be issued in ways that dilute or impede a takeover attempt, although the Board states that the amendment is not part of an anti-takeover plan. The Board unanimously recommends a vote FOR, asserting that the authorization is necessary to meet contractual obligations and preserve financial and strategic flexibility.
- 2
Other Business Properly Brought Before the Special Meeting
ManagementAuthorize the named proxies to use their discretion on any other business or matters that may properly come before the Special Meeting or any adjournment or postponement.
More detail
The proxy statement includes a standard authorization for the meeting to transact any other business that may properly come before the Special Meeting. This is not presented as a separately substantive corporate action with a defined resolution or requested business outcome. The Company states that its Board does not intend to bring any additional matters before stockholders. It also states that the Company is not currently aware of any other matters that may properly be presented by others. If a proper matter nevertheless arises, the named proxy holders will have discretionary authority to vote the represented shares. Their stated intention is to vote according to their best judgment. The proxy card likewise authorizes discretionary voting on other matters at the meeting or any adjournment or postponement. No specific board recommendation of FOR or AGAINST is provided because no particular additional matter has been identified. Accordingly, this item functions as a procedural catch-all rather than a substantive proposal for stockholder approval.
Nominees on the ballot
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 4.1% | 32,786,348 | $478M |
| 2 | STATE STREET CORP | 1.2% | 9,536,796 | $139M |
| 3 | FMR LLC | 0.8% | 6,514,396 | $95M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 0.7% | 5,734,484 | $84M |
| 5 | UBS Group AG | 0.6% | 5,159,918 | $75M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 0.6% | 5,042,190 | $73M |
| 7 | GOLDMAN SACHS GROUP INC | 0.5% | 4,219,688 | $61M |
| 8 | BlackRock, Inc. | 0.5% | 4,084,744 | $60M |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 0.5% | 3,743,023 | $55M |
| 10 | Point72 Asset Management, L.P.Activist | 0.5% | 3,697,803 | $54M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Summit Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Summit Therapeutics Inc 2026 special meeting?
- Summit Therapeutics Inc (SMMT) holds its 2026 special shareholder meeting on Wednesday, November 4, 2026.
- What is the record date for the Summit Therapeutics Inc 2026 meeting?
- The record date for the Summit Therapeutics Inc 2026 meeting is Thursday, October 1, 2026. Shareholders of record on or before that date are eligible to vote.
- What proposals will shareholders vote on at the Summit Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Summit Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.